Lilly maintains weight loss leadership as Foundayo, Zepbound keep pounds off after switching

Despite seeing some regain, patients in two trials maintained most of their weight loss after switching to either Foundayo or lower-dose Zepbound from other injectable incretin therapies.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top